相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems
Tore K. Kvien et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2022)
Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation
Kenta Haraya et al.
PHARMACEUTICALS (2022)
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity
Sihem Ait-Oudhia et al.
MABS (2017)
The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review
Winnie Sohn et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Biologics: An Update and Challenge of Their Pharmacokinetics
Shaojun Shi
CURRENT DRUG METABOLISM (2014)
Effects of Denosumab on Bone Turnover Markers in Postmenopausal Osteoporosis
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women
PJ Bekker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
分享论文
